Sep. 9 at 1:06 PM
$IFRX HCW- Con’t CSU:
“CSU represents a significant commercial opportunity. In the U.S., urticaria prevalence is estimated to
be 0.5-1% of the total population (approximately 1 to 3 million individuals). Estimates place the CSU market
value at approximately
$2 billion in the U.S., and a
$7-8 billion market for the indication worldwide.
Unfortunately, available therapies are limited and only provide symptomatic relief. Current options include:
1) antihistamines,
2) leukotriene receptor antagonists, 3) omalizumab (brand name XOLAIR),
$RHHBY
4) dupilumab (brand name DUPIXENT)
$SNY and
$REGN
https://www.barrons.com/articles/regeneron-blockbuster-dupixent-rival-ef230b36
